GlassScriptPhysician profile
Bryan J Garber
NPI 1669768438
$10,954.12
in general payments reported to CMS, 2019-2025
44 companies · $2,403 in 2025
The $2,403 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,336 · 2020: $1,176 · 2021: $1,217 · 2022: $1,734 · 2023: $842 · 2024: $1,246 · 2025: $2,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,412 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,411.98 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,868.59 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $1,385.77 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,152.30 | 2019-2025 | Fasenra, Airsupra, Andexxa |
| Mylan Specialty L.P. | $897.73 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $398.29 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $383.14 | 2019-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $379.95 | 2021-2025 | Tyvaso |
| Noctrix Health, INC. | $336.86 | 2025 | Nidra |
| Insmed, INC. | $318.31 | 2022-2025 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $285.97 | 2019-2025 | |
| Pfizer INC. | $246.58 | 2019-2025 | |
| La Jolla Pharmaceutical Company | $236.36 | 2019-2025 | Giapreza |
| Actelion Pharmaceuticals US, INC. | $208.37 | 2019-2022 | |
| Genzyme Corporation | $182.19 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $178.93 | 2019-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $178.35 | 2020-2022 | |
| Inari Medical, INC. | $168.40 | 2022 | |
| Harmony Biosciences LLC | $154.76 | 2020-2025 | |
| Portola Pharmaceuticals, LLC | $152.13 | 2019 | |
| Advanced Respiratory, INC | $143.34 | 2019-2021 | |
| Electromed, INC. | $126.73 | 2021-2025 | Smartvest |
| Genentech USA, INC. | $121.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $113.69 | 2023-2025 | Winrevair, Zerbaxa, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $112.80 | 2020-2025 | Glassia |
| Resmed Corp | $110.17 | 2020-2025 | |
| Viatris Specialty LLC | $108.80 | 2025 | Yupelri |
| Philips North America LLC | $103.88 | 2019-2025 | Vest Therapy Und |
| Paratek Pharmaceuticals, INC. | $103.12 | 2022-2025 | Nuzyra |
| Axsome Therapeutics, INC. | $101.13 | 2024-2025 | Sunosi |
| Baxter Healthcare | $79.36 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Lilly USA, LLC | $78.86 | 2025 | Zepbound |
| Amgen INC. | $63.11 | 2022-2023 | Tezspire |
| Shionogi INC | $59.13 | 2021-2025 | Fetroja |
| Mallinckrodt Hospital Products INC. | $57.52 | 2024 | Acthar |
| Pulmonx Corporation | $50.32 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Alexion Pharmaceuticals, INC. | $50.21 | 2022 | |
| Sunovion Pharmaceuticals INC. | $38.81 | 2019-2020 | |
| Tactile Systems Technology INC | $33.98 | 2025 | Nimbl, Flexitouch Plus |
| Allergan, INC. | $24.97 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $24.41 | 2025 | Lumryz |
| Inspire Medical Systems, INC. | $22.53 | 2025 | Inspire |
| Tetraphase Pharmaceuticals, INC. | $16.97 | 2019 | |
| Optinose US, INC. | $16.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Garber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.